Comment: This is a PEGylated version of recombinant human G-CSF. Pegylation increases circulating half-life. In addition to pegfilgrastim, lipegfilgrastim (Lonquex®) is a glyco-PEGylated long-acting G-CSF, that is an alternative to pegfilgrastim [
1].
Biosimilars: | Name | Trade name | Company | Approvals | Indications |
| pegfilgrastim-jmbd; MYL-1401H | Fulphila | Mylan/Biocon | 2018 FDA & EMA | As per reference agent [2] |
| | Pelgraz | Accord | 2018 EMA | As per reference agent |
| | Pelmeg | Mundipharma (developed by Cinfa Biotech) | 2018 EMA | As per reference agent |
| | pegfilgrastim Mundipharma | Mundipharma | 2019 EMA | As per reference agent |
| pegfilgrastim-cbqv; CHS-1701 | Udenyca | ERA Consulting; Coherus BioSciences | 2018 FDA & EMA | As per reference agent |
| USV pegfilgrastim | Grasustek | Juta Pharma | 2019 EMA | As per reference agent |
| pegfilgrastim-bmez; LA-EP2006 | Ziextenzo | Sandoz | 2018 EMA, 2019 FDA | As per reference agent |
| pegfilgrastim-apgf; PF-06881894 | Nyvepria | Pfizer | 2020 FDA | As per reference agent |
| pegfilgrastim-fpgk; MSB11455 | Stimufend | Fresenius Kabi | 2022 FDA & EMA | As per reference agent |
| pegfilgrastim-pbbk | Fylnetra | Amneal Pharmaceuticals | 2022 FDA | As per reference agent |
| pegfilgrastim biosimilar; BP14 | Dyrupeg | CuraTeQ Biologics | 2025 EMA | As per reference agent |
| pegfilgrastim biosimilar | Vivlipeg | Biocon/Biosimilar Collaborations Ireland | 2025 EMA | As per reference agent |
| pegfilgrastim biosimilar; BP14 | Dyrupeg | CuraTeQ Biologics/Aurobindo Pharma | 2025 EMA & UK MHRA | As per reference agent |